Tff Enterprise Value Over E B I T D A from 2010 to 2024
| TFFP Stock | USD 0.30 0.01 1.67% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (0.35) | Current Value (0.37) | Quarterly Volatility 6.5 K |
Check Tff Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tff Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 29.2 K, Selling General Administrative of 6.8 M or Research Development of 9.9 M, as well as many indicators such as Price To Sales Ratio of 13.72, Dividend Yield of 0.019 or PTB Ratio of 1.38. Tff financial statements analysis is a perfect complement when working with Tff Pharmaceuticals Valuation or Volatility modules.
Tff | Enterprise Value Over E B I T D A |
Latest Tff Pharmaceuticals' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Tff Pharmaceuticals over the last few years. It is Tff Pharmaceuticals' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tff Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Tff Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (6,750) | |
| Coefficient Of Variation | (96.74) | |
| Mean Deviation | 6,294 | |
| Median | (12,650) | |
| Standard Deviation | 6,529 | |
| Sample Variance | 42.6M | |
| Range | 12.6K | |
| R-Value | 0.87 | |
| Mean Square Error | 11.5M | |
| R-Squared | 0.75 | |
| Significance | 0.00003 | |
| Slope | 1,265 | |
| Total Sum of Squares | 596.8M |
Tff Enterprise Value Over E B I T D A History
About Tff Pharmaceuticals Financial Statements
Tff Pharmaceuticals shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Tff Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tff Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tff Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.35) | (0.37) |
Pair Trading with Tff Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tff Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tff Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Tff Stock
| 0.64 | VALN | Valneva SE ADR | PairCorr |
| 0.68 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Tff Stock
| 0.65 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.55 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | GILD | Gilead Sciences | PairCorr |
| 0.34 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Tff Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tff Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tff Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tff Pharmaceuticals to buy it.
The correlation of Tff Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tff Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tff Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tff Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Tff Stock Analysis
When running Tff Pharmaceuticals' price analysis, check to measure Tff Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tff Pharmaceuticals is operating at the current time. Most of Tff Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tff Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tff Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tff Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.